Cardiogenic Shock News and Research

RSS

Cardiogenic shock is based upon an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively.

Pre-hospital antiplatelet therapy offers no advantages for heart attack patients, study suggests

In contrast to European and American guidelines that recommend pre-hospital antiplatelet therapy for heart attack patients suffering from ST-elevation myocardial infarction (STEMI), a new study presented at ESC Congress1 suggests this practice has no advantage over waiting for in-ho

29 Aug 2017

New report highlights trends in heart disease care in the U.S.

Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to a broad report on trends in heart disease care from the American College of Cardiology's National Cardiovascular Data Registry published in the Journal of the American College of Cardiology.

18 Jan 2017

Drug that improves blood flow in damaged heart may be possible treatment option for TNBC

Researchers are looking at a drug once used to improve blood flow in damaged hearts in thousands of patients as a possible treatment option for triple negative breast cancer (TNBC).

6 Jan 2017

NCDR provides data to study appropriate use of oral anticoagulant therapy

The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.

30 Sep 2016

Intravenous beta blockers offer no clinical benefit to patients with STEMI

Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack—ST-segment elevation myocardial infarction (STEMI)—was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Heart attack patients experiencing cardiogenic shock at higher risk of death in first 60 days post-discharge

Heart attack patients who experience cardiogenic shock have a higher risk of death or rehospitalization than non-shock patients in the first 60 days post-discharge, but by the end of the first year, the gap between the two groups narrows, according to a study published today in the Journal of the American College of Cardiology.

16 Feb 2016

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

Physicians at UH Case Medical Center implant revolutionary device to treat right ventricular heart disease

University Hospitals Case Medical Center physicians in the Harrington Heart & Vascular Institute were the first in the state of Ohio to implant a revolutionary device to treat right ventricular heart disease.

5 Jun 2015

Routine use of thrombectomy in heart attack patients may increase risk of stroke

The largest study ever of its kind, led by researchers from McMaster University and the University of Toronto, has found that a routine strategy of blood clot removal during treatment for heart attacks was not beneficial and was associated with an increased risk of stroke.

17 Mar 2015

Studies evaluate traditional management of heart attack patients after discharge from hospital

Beta-blockers have been a cornerstone in the treatment of heart attack survivors for more than a quarter of a century. However, many of the data predate contemporary medical therapy such as reperfusion, statins, and antiplatelet agents, and recent data have called the role of beta-blockers into question.

12 Nov 2014

Experimental agent TRO40303 ineffective in patients with heart attack

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today as a Hot Line the ESC Congress 2014 with simultaneous publication in the European Heart Journal.

1 Sep 2014

Recommendations on arrhythmia management in ACS patients published in EP Europace

The first multidisciplinary recommendations on the management of arrhythmias in patients with acute coronary syndromes (ACS) are published today in EP Europace.

30 Aug 2014

Heart failure patients benefit from new device till transplant

The largest single-center study of patients implanted with a total artificial heart finds the device may help patients in severe heart failure survive until they can receive a heart transplant, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

28 Mar 2014

ECMO can be used for treating carbon monoxide poisoning

Allison Morgan was in pretty bad shape when the medical helicopter touched down on the rooftop helipad of the University of Alabama at Birmingham Hospital.

12 Mar 2014

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Cardiohelp assists heart by pumping blood to oxygenator in seriously ill patients

A viral infection was causing life-threatening heart failure in Loyola University Medical Center patient Michelle Rivera.

14 Mar 2013

ECMO and mechanical CPR use can lead to unexpected survival in severe heart attack patients

The use of extracorporeal membrane oxygenation (ECMO), accompanied by mechanical CPR, in patients with massive myocardial infarctions can lead to unexpected survival. These study findings are being presented March 9 at the American College of Cardiology Scientific Sessions.

12 Mar 2013

Failure to use aspirin before angioplasty increases death rate

Despite recommendations from leading medical groups, a surprising number of patients are not given aspirin before artery-clearing coronary angioplasty and stenting, and those patients have a significantly higher in-hospital death rate, according to research from a Michigan network being presented at the American College of Cardiology's 62nd Annual Scientific Session.

8 Mar 2013

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012